Kim Narunsky

2.2k total citations
16 papers, 751 citations indexed

About

Kim Narunsky is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Kim Narunsky has authored 16 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 7 papers in Pharmacology and 7 papers in Epidemiology. Recurrent topics in Kim Narunsky's work include Tuberculosis Research and Epidemiology (15 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Cancer therapeutics and mechanisms (4 papers). Kim Narunsky is often cited by papers focused on Tuberculosis Research and Epidemiology (15 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Cancer therapeutics and mechanisms (4 papers). Kim Narunsky collaborates with scholars based in South Africa, United States and Netherlands. Kim Narunsky's co-authors include Rodney Dawson, Andreas H. Diacon, Amour Venter, Peter R. Donald, M. Hanekom, Jeannine du Bois, Melvin Spigelman, Christo van Niekerk, Ann M. Ginsberg and Lawrence Geiter and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kim Narunsky

15 papers receiving 728 citations

Peers

Countries citing papers authored by Kim Narunsky

Since Specialization

Citations

This map shows the geographic impact of Kim Narunsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Narunsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Narunsky more than expected).

Fields of papers citing papers by Kim Narunsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Narunsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Narunsky. The network helps show where Kim Narunsky may publish in the future.

Co-authorship network of co-authors of Kim Narunsky

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Narunsky. A scholar is included among the top collaborators of Kim Narunsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Narunsky. Kim Narunsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043 2025 ·Journal of Antimicrobial Chemotherapy ·(unknown), Norbert Heinrich, Veronique de Jager, (unknown), Patrick Phillips, (unknown), Rodney Dawson, Kim Narunsky, Letícia Muraro Wildner, Timothy D. McHugh, Lindsey H. M. te Brake, Andreas H. Diacon, Rob E. Aarnoutse, Michael Höelscher, Elin M. Svensson	1
2	Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial 2024 ·The Lancet Infectious Diseases ·Rodney Dawson, Andreas H. Diacon, Veronique de Jager, Kim Narunsky, Vineshree Mischka Moodley, (unknown), Yongge Liu, Bo Zheng, Jeffrey Hafkin	4
3	Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), Veronique de Jager, Rodney Dawson, Andreas H. Diacon, Kim Narunsky, Sherman D. Padayachee, Martin J. Boeree, (unknown), (unknown), Marieke J. H. Coenen, Elin M. Svensson, Uwe Fuhr, Patrick Phillips, Lindsey H. M. te Brake, Rob E. Aarnoutse	6
4	Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832 2023 ·Antimicrobial Agents and Chemotherapy ·Rodney Dawson, Andreas H. Diacon, Kim Narunsky, Veronique de Jager, (unknown), Xiaoyan Zhang, Yongge Liu, Jeffrey Hafkin	7
5	Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results 2022 ·American Journal of Respiratory and Critical Care Medicine ·Kelly E. Dooley, (unknown), (unknown), Grace L. Barnes, Kim Narunsky, (unknown), Tanya Smit, Elisa H. Ignatius, (unknown), Susan E. Dorman, Rodney Dawson	10
6	Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial 2021 ·BMC Infectious Diseases ·(unknown), Anne‐Marie Demers, Soyeon Kim, Sara McCallum, Kathleen D. Eisenach, Michael D. Hughes, (unknown), Alberto Mendoza‐Ticona, Neeta Pradhan, Kim Narunsky, Selvamuthu Poongulali, Sharlaa Badal‐Faesen, Caryn M. Upton, Elizabeth Smith, N. Sarita Shah, Gavin Churchyard, Amita Gupta, Anneke C. Hesseling, Susan Swindells	5
7	Resistance toMycobacterium tuberculosisInfection Among Household Contacts: A Multinational Study 2021 ·Clinical Infectious Diseases ·Davit Baliashvili, Neel R. Gandhi, Soyeon Kim, Michael D. Hughes, Vidya Mave, Alberto Mendoza‐Ticona, Pedro Gonzáles, Kim Narunsky, Poongulali Selvamuthu, Sharlaa Badal‐Faesen, Caryn M. Upton, (unknown), Elizabeth Smith, Amita Gupta, Gavin Churchyard, Susan Swindells, Anneke C. Hesseling, Neha Shah	10
8	Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg⁻¹rifampicin 2021 ·European Respiratory Journal ·Lindsey H. M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Höelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree	36
9	Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis 2020 ·Antimicrobial Agents and Chemotherapy ·Elisa H. Ignatius, (unknown), (unknown), (unknown), Kim Narunsky, Lubbe Wiesner, Grace L. Barnes, Rodney Dawson, Kelly E. Dooley, Paolo Denti	15
10	Increased Bactericidal Activity But Dose-Limiting Tolerability at 50 mg/kg Rifampicin 2020 ·SSRN Electronic Journal ·Lindsey te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Höelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse, Martin J. Boeree	0
11	Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis 2020 ·Antimicrobial Agents and Chemotherapy ·Andreas H. Diacon, Veronique de Jager, Rodney Dawson, Kim Narunsky, Naadira Vanker, Divan A. Burger, Daniel E. Everitt, Frances Pappas, Jerry Nedelman, Carl M. Mendel	23
12	A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis 2015 ·American Journal of Respiratory and Critical Care Medicine ·Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Kim Narunsky, Jeannine du Bois, Amour Venter, Patrick Phillips, Stephen H. Gillespie, Timothy D. McHugh, Michael Höelscher, Norbert Heinrich, Sunita Rehal, Dick van Soolingen, Jakko van Ingen, Cécile Magis-Escurra, David M. Burger, Georgette Plemper van Balen, Rob E. Aarnoutse	213
13	Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis 2015 ·The International Journal of Tuberculosis and Lung Disease ·Rodney Dawson, Kim Narunsky, (unknown), (unknown), Andrew Whitelaw, (unknown), Grace L. Barnes, James Hoffman, Richard E. Chaisson, Helen McIlleron, Susan E. Dorman	9
14	Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 2012 ·Antimicrobial Agents and Chemotherapy ·Andreas H. Diacon, Rodney Dawson, Jeannine du Bois, Kim Narunsky, Amour Venter, Peter R. Donald, Christo van Niekerk, Ngozi Erondu, Ann M. Ginsberg, Piet Becker, Melvin Spigelman	109
15	Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients 2011 ·The International Journal of Tuberculosis and Lung Disease ·Andreas H. Diacon, Rodney Dawson, M. Hanekom, Kim Narunsky, Amour Venter, Norbert Hittel, Lawrence Geiter, Charles D. Wells, Anne Paccaly, Peter R. Donald	157
16	Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients 2010 ·Antimicrobial Agents and Chemotherapy ·Andreas H. Diacon, Rodney Dawson, M. Hanekom, Kim Narunsky, (unknown), Amour Venter, Peter R. Donald, Christo van Niekerk, Karl Whitney, D.J. Rouse, Martino Laurenzi, Ann M. Ginsberg, Melvin Spigelman	146

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact